164 related articles for article (PubMed ID: 32112240)
1. Recombinant human thyrotropin versus thyroid hormone withdrawal in an Asian population.
Tang CYL; Thang SP; Zaheer S; Kwan CK; Ng DC
Endocrine; 2020 Jul; 69(1):126-132. PubMed ID: 32112240
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
6. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
[TBL] [Abstract][Full Text] [Related]
8. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
10. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
12. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
13. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
[TBL] [Abstract][Full Text] [Related]
17. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
20. Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
Lin YS; Yang H; Li XY; Wu LQ; Xu JG; Yang AM; Gao ZR; Ding Y; Zhang YQ; Chen K; Mu ZZ; Jia JM; Niu N; Sun D; Zhang X; Zhang SQ; Geng QQ; Zhang YJ; Chen FN; He BX
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4171-4181. PubMed ID: 35781600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]